Articles tagged with Lung Cancer
Researchers at Wake Forest School of Medicine have identified a set of new genetic markers that could lead to targeted treatments for non-small cell lung cancer. The study found that tumors with mutated KMT2 genes exhibit genetic instability, making them more sensitive to PARP inhibitors.
A team of researchers has developed AI tools to predict which lung cancer patients will respond to immunotherapy, with the goal of improving patient outcomes and reducing costs. The study uses machine learning algorithms to analyze tissue scan patterns and identify previously unseen indicators that can inform treatment decisions.
The cancer burden in China has undergone a paradigm shift, with rising cases of breast and lung cancers. The country's high incidence rate makes it a priority for policymakers to implement tailored preventive measures, including health education, vaccination programs, and tobacco-control policies.
Researchers found a novel genomic signature associated with increased risk of early death from lung cancer. Patients with high expression of these genes have indicators of immune system activity, but also suppressed T cells, which can impact treatment effectiveness.
Two researchers from the University of Minnesota Medical School will lead a new VA-funded network to expand lung cancer screenings and research among veterans in the Upper Midwest region. The $4.5 million grant aims to increase veteran access and participation in lung cancer clinical trials, addressing barriers such as distance travel,...
The IASLC Molecular Database Project seeks to accelerate understanding of lung cancer biology, clinical care, and global scale. It aims to provide a platform for deeper, broader understanding of molecular testing and targeted therapy.
The new guidelines recommend yearly low-dose CT scans for Americans aged 50-80 with a 20 pack-year smoking history or those who quit less than 15 years ago. The expanded criteria aim to reduce lung cancer disparities in Black people and women.
Updated USPSTF guidelines based on age, pack-years, and quit-years exacerbate eligibility disparities among racial and ethnic minorities. However, incorporating certain risk prediction models may help mitigate these inequalities, according to a study published in the American Journal of Roentgenology.
A new study found that a second drug targeting KRASG12C showed promising results in treating non-small-cell lung cancer (NSCLC) with this specific mutation. Nearly half of patients evaluable for clinical activity had a partial response to treatment, setting up potential future trials and combinations.
A new lymph node collection kit has been shown to improve long-term survival after curative-intent lung cancer surgery. The kit helps surgeons attain complete resection by improving pathologic nodal evaluation, leading to a significant increase in R0 resections and reduction in non-examination of lymph nodes.
Researchers discovered that glucose metabolism in tumor-associated neutrophils determines their tumor-supportive behavior in lung cancer development. Removing Glut1 from these cells reduces tumor growth rate but increases radiotherapy efficacy.
Researchers at Baylor College of Medicine have identified 25 rare genetic variants associated with increased risk of lung cancer. These variants, which include insertions and deletions, lead to genomic instability and increase DNA damage, suggesting a potential role in cancer development.
A study reveals that over one in ten lung cancer patients are unsure of their tumor type, highlighting the need for improved communication between patients and healthcare providers. Language differences and complex treatments contribute to these misunderstandings, jeopardizing patient care.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
A comprehensive review of lung cancer screening trials reveals both benefits and harms, leading to updated USPSTF recommendations. Screening can lower lung cancer deaths in high-risk individuals, but also leads to false positives and unnecessary procedures.
Researchers developed a new method to detect circulating tumor cells in NSCLC patients, identifying a CK-negative CTC population associated with metastasis and drug resistance. The use of hexokinase-2 as a biomarker revealed this novel CTC population in 50% of analyzed patients.
The new USPSTF recommendation doubles the number of eligible adults for lung cancer screening from 6.4 million to 14.5 million. However, experts argue that this expansion may not address racial inequities and highlights the need for individualized risk assessment and genetic risk models.
Experts recommend shared decision-making between patients and doctors before low-dose CT scans for lung cancer screening to ensure informed consent. The process can promote patient engagement, tobacco cessation, and screening adherence, leading to greater health equity.
Researchers at KIST discovered that red ginseng can significantly suppress lung cancer metastasis, with components Rk1 and Rg5 showing effective inhibition. The study developed a microwave processing method to increase the concentration of these components, leading to potential anti-cancer effects.
Moffitt researchers found that epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy, with varying levels of sensitivity. The study suggests that targeting alternative signaling pathways, such as HER2 and FGFR1, may enhance treatment efficacy.
A team led by Dr. Brian Brown is developing a CAR T-cell therapy that specifically targets immune-suppressing macrophages in tumors, clearing the way for other T cells to destroy cancer cells. The grant aims to advance this promising approach and bring new hope to patients with solid tumor cancers.
The NEOSTAR trial found that combination therapy produced significant clinical benefits, including higher major pathologic response rates and enhanced tumor immune cell infiltration. The treatment also triggered immunological memory, which may translate to a reduced risk of tumor relapse.
Researchers developed a deep learning model that accurately predicts lung cancer patients' survival expectancy, significantly better than traditional machine learning models. The model can analyze large amounts of data to understand how various factors affect lung cancer survival periods.
A study published in Oncotarget found that hemoglobin-based oxygen carriers increase chemotherapy effectiveness in non-small cell lung cancer. PolyHb administration attenuates tumor growth without alleviating hypoxia, suggesting a potential strategy to enhance cisplatin sensitivity.
A new algorithm developed by researchers at the University of Copenhagen can detect unusual disease trajectories in COPD patients that may indicate a different diagnosis, such as lung cancer. The algorithm was trained on data from 284,000 patients and identified approximately 69,000 typical disease trajectories.
Lung cancer is a leading cause of death in Singapore and the world, with Asian populations exhibiting distinct genetic alterations. The World Conference on Lung Cancer Singapore presented new data on EGFR mutation and TKI-drug resistance, highlighting the need for targeted treatment approaches.
Patients with non-small cell lung cancer who enrolled in a phase III early-stage trial showed a high rate of smoking reduction and cessation following study entry. Smoking rates were significantly lower among never-smokers, leading to improved overall survival compared to smokers.
The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
The LCMC3 study showed that neoadjuvant atezolizumab was well tolerated and met its primary endpoint, achieving a major pathologic response rate of 21% in patients without EGFR/ALK mutations. The therapy also showed high complete resection rates and low perioperative morbidity and mortality.
A nationwide lung cancer LDCT screening study found the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker population. The study revealed that family history significantly increased lung cancer risk, and most participants had stage 0 or 1 disease.
A host immune classifier test may help guide immunotherapy treatment decisions for patients with newly diagnosed non-small cell lung cancer. The test, which measures inflammation in the body, is associated with longer overall survival and better treatment response.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.
Two ADAURA analyses presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore support the use of Osimertinib as a new treatment strategy for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer. The data show significant disease-free surviva...
Researchers presented two radiation oncology trials that aimed to improve local tumor control in NSCLC patients. One trial found no significant difference in 2-year local-regional tumor progression-free rates between adaptive and standard radiation therapy arms, while another study demonstrated excellent local control rates with dose e...
Researchers investigating lung cancer treatment during the pandemic found that patients with lung cancer experience higher levels of psychological distress and anxiety about accessing care. The study also revealed that patient advocacy organizations face challenges in providing support due to decreased funding.
Researchers found that combining ipilimumab with pembrolizumab did not significantly improve overall survival or progression-free survival for patients with NSCLC. The combination was also associated with greater treatment-related adverse events.
Research found that black patients diagnosed with non-small cell lung cancer are more likely to be diagnosed at an advanced stage and have lower chances of receiving surgery. Additionally, they experience significantly reduced cancer-specific survival rates compared to their white counterparts.
Research highlights barriers to lung cancer care for marginalized communities, including racial and ethnic minorities, LGBTQ+ individuals, and low-income patients. Key findings also show sex disparities in lung cancer incidence rates across countries.
The NRG Oncology trial shows improved in-field tumor control with adaptive radiotherapy, increasing local-regional tumor control by 11% and primary tumor control by 17%. The study's results suggest individualizing radiotherapy dose prescriptions according to patient's intrinsic sensitivity for better survival outcomes.
In the phase II CodeBreak 100 trial, sotorasib demonstrated a confirmed response rate of 32.2%, a median duration of response of 10.9 months, and a median progression-free survival of 6.3 months in patients with pretreated NSCLC and KRAS p.G12C mutations.
Researchers have developed a new method, Cell Heterogeneity-Adjusted cLonal Methylation (CHALM), that improves the prediction of gene expression from DNA methylation data. This method has been shown to identify more reliable biomarkers for cancer diagnosis, potentially leading to better early detection.
Researchers at McMaster University have developed a novel combination of two immunotherapies that induces robust tumour destruction against lung cancer. The new treatment uses one form of therapy to kill cancer cells and triggers changes that enable the second therapy to finish the job.
A study in Journal of Thoracic Oncology found that routine thoracic surgery and invasive examinations were performed safely during the COVID-19 pandemic. The study analyzed data from a single Chinese hospital and showed that careful screening, patient protection, and effective medical staff precautions enabled safe operations.
A recent study by University of Cincinnati Cancer Center researchers shows that the pandemic had a negative impact on both preventive screening and patient outcomes for lung cancer. The team found that total monthly CT scans and new patient scans significantly decreased during the COVID-19 period, leading to increased proportion of sus...
A recent study reported a significant drop in low-dose computed tomography (LDCT) screening for lung cancer during the COVID-19 pandemic. Despite resuming full operations, new patient monthly LDCT rates remained low, and patients were more likely to miss appointments, increasing the no-show rate from 15% to 40%. This led to a rise in m...
Researchers at Temple University Health System aim to break down race-related barriers to lung cancer screening and care among Blacks and African Americans. The two-year grant will support the expansion of a successful lung cancer screening program using a multi-specialty, integrated model.
A study has found that certain types of mouth bacteria are associated with an increased risk of lung cancer in non-smokers. The findings suggest that a wider range of bacterial species is linked to a lower risk, while specific types like Firmicutes and Spirochaetes may contribute to heightened risk.
Scientists have developed a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. The treatment has shown promise in treating aggressive subtypes of cancers with specific mutations in genes called RAS or NF1.
The new guidelines provide uniform standards for treating brain tumour complications such as epileptic attacks, brain edema, haemorrhage, or thrombosis worldwide. The initiative aims to increase patient safety and improve treatment outcomes.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new target for aggressive lung adenocarcinomas driven by the KEAP1 and STK11 mutations. By inhibiting ferroptosis, these tumors rely on this blockade to grow and survive.
Research suggests stress hormones and immune cells may contribute to tumor recurrence by reactivating dormant cancer cells. Targeting stress hormones with approved drugs like beta-blockers could potentially prevent tumors from returning.
A new study has shed light on the role of p53 target gene Zmat3 in lymphoma and lung cancer development. Researchers found that disabling Zmat3 had little impact on tumor development, suggesting that other proteins may be involved in preventing cancer formation.
Researchers found an overall 17% risk reduction for metastatic or fatal cancer and a 38% reduction among those with normal BMI. The study suggests that vitamin D may reduce the risk of developing advanced cancers, particularly in individuals with normal weight.
A study led by Massachusetts General Hospital found that early treatment with lorlatinib improved survival rates and reduced the risk of brain metastasis in ALK-positive lung cancer patients. Lorlatinib was shown to be effective as a first-line therapy, reducing the risk of cancer progression or death by 72%.
A study by University of Utah researchers found that experienced radiologists can miss clear abnormalities when looking for one specific issue, highlighting the limits of human cognition. The experiment demonstrates that years of experience don't guarantee detection of critical findings.
Researchers found patients with a particular type of human leukocyte antigen (HLA) B44 were more likely to benefit from immunotherapy in melanoma but not non-small cell lung cancer. The study identified mutations driving the different responses, paving the way for better patient stratification and potential therapy design.
A new model predicts the risk of severe side effects in cancer patients during chemotherapy by analyzing genetic signatures. The study identified a network of genes linked to bone marrow toxicity and developed a classification system to predict patient risk.
A study published in Cancer Discovery found that patients with advanced-stage lung cancer had greater enrichment of oral commensals in the lung than those with early-stage disease, leading to decreased survival. The presence of specific bacteria was associated with tumor progression and activation of inflammatory pathways.
Researchers from MD Anderson Cancer Center present promising clinical data on combination therapies for patients with metastatic melanoma and advanced refractory solid tumors. The treatments showed activity in activating immune pathways, leading to antitumor responses.